Table Demographic and baseline characteristics of patients treated with defibrotide post allogeneic-HCT.

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

 

Matched sibling donor

Matched unrelated donor

Mismatched unrelated donor

Haplo-identical donor

All allografta

 

n = 86

n = 92

n = 41

n = 50

n = 288

Age (year)

     

Median (Min, Max)

48 (1, 69)

47 (1, 71)

38 (2, 68)

50 (9, 74)

46 (0, 74)

Age group, n (%)

     

Age <18 years

Age ≥18 years

15 (17.4)

71 (82.6)

17 (18.5)

75 (81.5)

14 (34.1)

27 (65.9)

2 (4.0)

48 (96.0)

62 (21.5)

226 (78.5)

Sex

     

(%) Male

57 (66.3)

52 (56.5)

25 (61.0)

26 (52.0)

169 (58.7)

VOD/SOS severityb

     

Mild/Moderate

Severe

Very severe

20 (23.3)

36 (41.9)

30 (34.9)

19 (20.9)

30 (33.0)

42 (46.2)

15 (36.6)

14 (34.1)

12 (29.3)

8 (16.3)

18 (36.7)

23 (46.9)

66 (23.1)

101 (35.3)

119 (41.6)

Primary disease, n (%)c

     

ALL

AML

MDS

Lymphoma

11 (12.8)

31 (36.0)

8 (9.3)

17 (19.8)

27 (29.3)

20 (21.7)

14 (15.2)

11 (12.0)

10 (24.4)

16 (39.0)

9 (22.0)

0 (0.0)

10 (20.0)

18 (36.0)

9 (18.0)

7 (14.0)

65 (22.6)

88 (30.6)

38 (13.2)

42 (14.6)

  1. a18 patients had umbilical cord blood donors; one patient had non-HLA matching data was missing from one non-parent donor.
  2. bVOD severity data was missing from two adults (one with matched unrelated donor, one with haplo-identical donor). The denominators used to calculate the percentage of severity were 91 for patients with matched unrelated donor and 49 for patients with haplo-identical donor.
  3. cPrimary disease occurred in ≥10.0% of patients in any group.
  4. ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; HCT, haematopoietic cell transplantation; SOS, sinusoidal obstruction syndrome; VOD, veno-occlusive disease.
Back to article page